Back to Search
JUDITH OCHS, MD
MD
Pediatric Infectious Diseases Physician
NPI: 1528434495Individual
Specialties, Licenses & Credentials
Pediatric Infectious Diseases PhysicianPrimary
Pediatrics — Pediatric Infectious Diseases
Code: 2080P0208X
MD427482(PA)
Research & Publications (20)
Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy.
PMID 18787840·J Cancer Res Clin Oncol·2009
8-other
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
PMID 16467100·Clin Cancer Res·2006
3-trial
Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program.
PMID 16797779·Lung Cancer·2006
3-trial
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
PMID 16204011·J Clin Oncol·2005
3-trial
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
PMID 15699477·J Clin Oncol·2005
3-trial
Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors.
PMID 14967454·Int J Radiat Oncol Biol Phys·2004
6-review
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
PMID 14990633·J Clin Oncol·2004
3-trial
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
PMID 14990632·J Clin Oncol·2004
3-trial
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
PMID 14570950·JAMA·2003
3-trial
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
PMID 12796366·Clin Cancer Res·2003
8-other
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
PMID 12775734·J Clin Oncol·2003
3-trial
Increased plasma endothelin-1 levels in fibromyalgia syndrome.
PMID 12626812·Rheumatology (Oxford)·2003
8-other
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.
PMID 12499095·Lung Cancer·2003
8-other
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
PMID 12228201·J Clin Oncol·2002
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1213 FAIRVILLE ROAD
CHADDS FORD, PA 19317 - Phone
- (610) 388-1770
Quick Facts
- NPI
- 1528434495
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile